ReproductiveIn Clinical Trials

Carbetocin

Intravenous, Intramuscular injection

Overview

A long-acting synthetic analog of oxytocin with a modified disulfide bridge that confers resistance to enzymatic degradation. Carbetocin has a half-life of approximately 40 minutes compared to 3-5 minutes for oxytocin, providing sustained uterotonic activity after a single injection.

Mechanism of Action

It selectively binds oxytocin receptors in the myometrium, promoting uterine contraction and reducing postpartum blood loss..

Research Summary & Key Findings

WHO recommends heat-stable carbetocin for prevention of postpartum hemorrhage in settings where oxytocin cold chain cannot be maintained. CHAMPION trial (Widmer et al., NEJM, 2018) demonstrated non-inferiority to oxytocin for preventing blood loss at caesarean delivery. Approved in over 30 countries; not yet FDA-approved in the United States.

Clinical Status

In Clinical Trials

Carbetocin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

IntravenousIntramuscular injection

Related Peptides in Reproductive

Find a Provider

Find a verified provider who offers Carbetocin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Carbetocin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.